This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's How STERIS (STE) is Placed Ahead of Q1 Earnings
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results are likely to reflect the positives of the normalization of the Healthcare backlog, along with a core focus on pharma and MedTech.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Within Bio-Rad's (BIO) Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely impacted sales.
Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings
by Zacks Equity Research
IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release
by Zacks Equity Research
Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.
Globus Medical (GMED) Global Sales, Innovation Aid Growth
by Zacks Equity Research
In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.
Will Clear Aligner Sales Drive Align Technology's (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology's (ALGN) second-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.
Hologic's (HOLX) Surgical Business Set to Propel Q3 Earnings
by Zacks Equity Research
Hologic (HOLX) is likely to have delivered impressive performances across the GYN Surgical and Breast Health businesses in the third quarter of fiscal 2024.
Will Patient Volumes Drive Universal Health's (UHS) Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 performance is likely to gain from strong performances in its Acute Care Hospital Services and Behavioral Health Care Services segments.
Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D
by Zacks Equity Research
Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.
Comcast (CMCSA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Comcast's (CMCSA) second-quarter 2024 results are expected to reflect a slowing broadband subscriber base, offset by the steady performance of theme parks and the Peacock streaming service.
Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note
by Zacks Equity Research
QIAGEN's (QGEN) progress in test menu expansion, prospects in molecular diagnostics and strong solvency bode well.
Elevance Health's (ELV) Q2 Earnings Beat on Lower Benefit Expense
by Zacks Equity Research
Elevance Health's (ELV) Q2 results gain on strong product revenue growth in the Carelon business and a reduced overall expense level. Adjusted earnings are reiterated to be at a minimum of $37.20 per share in 2024.
Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings
by Zacks Equity Research
Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $23.11, indicating a +1.18% shift from the previous trading day.
Hyperfine (HYPR) to Release ACTION PMR Study Data for Swoop
by Zacks Equity Research
Hyperfine (HYPR) is set to release study data in August 2024, showing the value of the Swoop system in enabling critical stroke treatment choices in urgent care settings.
Integra's (IART) New Site to Produce Recalled Tissue Products
by Zacks Equity Research
Integra (IART) is set to recommence the manufacturing of PriMatrix and SurgiMend at its new facility in Braintree, MA.
Should You Keep Chemed (CHE) Stock in Your Portfolio Now?
by Zacks Equity Research
Chemed's (CHE) robust VITAS business and strong financial stability raise investors' optimism.
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
by Zacks Equity Research
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.
Alcon (ALC) Rides on Innovation, Balanced Segmental Sales
by Zacks Equity Research
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.
Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services
by Zacks Equity Research
Quest Diagnostics' (DGX) new agreement is likely to help expand access to cost-effective and advanced laboratory services in Ohio.
Haemonetics (HAE) Banks on Growing Hospital Arm, New Launches
by Zacks Equity Research
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.
What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?
by Zacks Equity Research
Quest Diagnostics (DGX) is likely to have maintained its robust base business performance in the second quarter of 2024. However, nosediving COVID-19 testing revenues may limit growth.
Is It Wise to Retain Henry Schein (HSIC) in Your Portfolio Now?
by Zacks Equity Research
Robust acquisitions and a widespread distribution network bode well for Henry Schein's (HSIC) operations.
Thermo Fisher (TMO) Inks New Partnership for myeloMATCH Trial
by Zacks Equity Research
Thermo Fisher (TMO) announces a partnership with the National Cancer Institute for the myeloMATCH precision medicine umbrella trial to fuel research regarding new treatments for AML and MDS.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.